{"id":"dor","safety":{"commonSideEffects":[{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Somnolence"}]},"_chembl":{"chemblId":"CHEMBL2364608","moleculeType":"Small molecule","molecularWeight":"425.75"},"_dailymed":{"setId":"1d94bcb1-e7ac-461f-9da4-05c10df2e82c","title":"DORAMECTIN POWDER [LIVZON NEW NORTH RIVER PHARMACEUTICAL CO., LTD.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Delta opioid receptors are G-protein coupled receptors involved in pain modulation, mood regulation, and other physiological processes. By selectively activating these receptors, DOR produces analgesic and potentially mood-enhancing effects. The selective delta agonism may offer a different safety and efficacy profile compared to mu opioid receptor agonists.","oneSentence":"DOR is a delta opioid receptor agonist that binds to and activates delta opioid receptors in the central and peripheral nervous system.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:09:46.906Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic pain conditions"}]},"trialDetails":[{"nctId":"NCT04223791","phase":"PHASE3","title":"Switch to Doravirine/Islatravir (DOR/ISL) in Human Immunodeficiency Virus 1 (HIV-1) Participants Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-018)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-02-18","conditions":"HIV Infection","enrollment":643},{"nctId":"NCT04948658","phase":"","title":"Gonadal Tissue Freezing for Fertility Preservation in Individuals at Risk for Ovarian Dysfunction, Premature Ovarian Insufficiency and Clinically Indicated Gonadectomy","status":"RECRUITING","sponsor":"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","startDate":"2021-09-13","conditions":"Turner Syndrome, Post-menarcheal Adolescents, Ovarian Disfunction","enrollment":200},{"nctId":"NCT05277948","phase":"NA","title":"Effect of Thumbtack Needle (TN) on Ovarian Reserve Function of Women With Diminished Ovarian Reserve (DOR)","status":"COMPLETED","sponsor":"Dongmei Huang","startDate":"2021-10-18","conditions":"Diminished Ovarian Reserve","enrollment":240},{"nctId":"NCT04375800","phase":"PHASE2","title":"Doravirine (DOR) in Human Immunodeficiency Virus (HIV)-Infected Children Aged 4 Weeks to <12 Years and <45 kg (MK-1439-066)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-02-03","conditions":"Human Immunodeficiency Virus (HIV) Infection","enrollment":84},{"nctId":"NCT07086079","phase":"PHASE1","title":"A Study of Doravirine/Islatravir in Healthy Lactating Females (MK-8591A-061)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-09-26","conditions":"Healthy","enrollment":12},{"nctId":"NCT04223778","phase":"PHASE3","title":"Safety and Efficacy of a Switch to Doravirine/Islatravir in Participants With HIV-1 (MK-8591A-017)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-02-18","conditions":"HIV Infection","enrollment":672},{"nctId":"NCT04695171","phase":"","title":"LINX Reflux Management System or Fundoplication Clinical Study in Patients With Hiatal Hernia >3 cm","status":"TERMINATED","sponsor":"Foregut Research Foundation","startDate":"2021-01-14","conditions":"Hiatal Hernia Large, Gastro Esophageal Reflux, Hiatal Hernia","enrollment":336},{"nctId":"NCT04736121","phase":"NA","title":"Selective Internal Radiation Therapy (SIRT) Using SIR-Spheres® Y-90 Resin Microspheres on DoR & ORR in Unresectable Hepatocellular Carcinoma Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sirtex Medical","startDate":"2021-05-28","conditions":"Unresectable Hepatocellular Carcinoma, BCLC Stage A Hepatocellular Carcinoma, BCLC Stage B Hepatocellular Carcinoma","enrollment":100},{"nctId":"NCT04233879","phase":"PHASE3","title":"Study of Doravirine/Islatravir (DOR/ISL 100 mg/0.75 mg) to Evaluate the Antiretroviral Activity, Safety, and Tolerability in Treatment-Naïve Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-020)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-02-28","conditions":"HIV-1 Infection","enrollment":599},{"nctId":"NCT05421806","phase":"","title":"A Cohort Study of Use of Doravirine (DOR) Based Regimens in Clinical Practice in Europe DoRavirine Europe Real World/","status":"ACTIVE_NOT_RECRUITING","sponsor":"NEAT ID Foundation","startDate":"2022-10-10","conditions":"HIV I Infection","enrollment":500},{"nctId":"NCT04776252","phase":"PHASE3","title":"Open-label, Follow-up of Doravirine/Islatravir (DOR/ISL 100 mg/0.75mg) for Participants With Human Immunodeficiency Virus-1 (HIV-1) Infection (MK-8591A-033)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-09-15","conditions":"HIV-1 Infection","enrollment":2000},{"nctId":"NCT07296614","phase":"PHASE3","title":"Clinical Evaluation of Integrated Chinese-Western Medicine for Infertility With DOR Patients in Women Achieving Natural Pregnancy","status":"NOT_YET_RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2025-12-25","conditions":"Diminished Ovarian Reserve (DOR), Infertility","enrollment":320},{"nctId":"NCT05766501","phase":"PHASE3","title":"A Study of Doravirine/Islatravir (DOR/ISL, MK-8591A) for the Treatment of Human Immunodeficiency Virus 1 (HIV-1) Infection in Participants Who Previously Received DOR/ISL (MK-8591A-054)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-03-17","conditions":"HIV Infection","enrollment":641},{"nctId":"NCT05631093","phase":"PHASE3","title":"A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Antiretroviral Therapy (ART) (MK-8591A-051)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-02-20","conditions":"HIV-1 Infection","enrollment":553},{"nctId":"NCT05630755","phase":"PHASE3","title":"A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-052)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-02-17","conditions":"HIV-1 Infection","enrollment":514},{"nctId":"NCT06630299","phase":"PHASE3","title":"Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2024-10-08","conditions":"HIV-1-Infection","enrollment":600},{"nctId":"NCT04518228","phase":"","title":"Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-09-01","conditions":"HIV Infections, Tuberculosis","enrollment":205},{"nctId":"NCT05705349","phase":"PHASE3","title":"DOR/ISL in HIV-1 Antiretroviral Treatment-naïve Participants (MK-8591A-053)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-03-08","conditions":"HIV-1 Infection","enrollment":537},{"nctId":"NCT07181070","phase":"","title":"The Use of Indocyanine Green Fluorescence (ICG) During Laparoscopic Heller- Dor","status":"RECRUITING","sponsor":"Federico II University","startDate":"2022-11-01","conditions":"Achalasia, Esophageal, Achalasia, Indocyanine Green (ICG)","enrollment":70},{"nctId":"NCT07142187","phase":"NA","title":"The Clinical Trial of Electro-thumbtack Needle on Live Birth Rate in Patients With Ovarian Reserve Dysfunction (DOR)","status":"NOT_YET_RECRUITING","sponsor":"Huazhong University of Science and Technology","startDate":"2025-10-01","conditions":"Diminished Ovarian Reserve (DOR)","enrollment":368},{"nctId":"NCT07075146","phase":"PHASE3","title":"DOR/TDF/3TC COmpared With BIC/FTC/TAF in ART-Naïve People Living With HIV and Overweight or Obesity","status":"RECRUITING","sponsor":"José Antonio Mata Marín","startDate":"2025-05-05","conditions":"HIV - Human Immunodeficiency Virus, Obesity, Overweight and/or Obesity","enrollment":306},{"nctId":"NCT07060755","phase":"NA","title":"Effect of Different Foot Baths on Postpartum Insomnia and Fatigue","status":"NOT_YET_RECRUITING","sponsor":"University of Yalova","startDate":"2025-09-01","conditions":"Postpartum","enrollment":90},{"nctId":"NCT07022886","phase":"","title":"INCIDENCE, PREVALENCE AND OVERALL RISK OF ESOPHAGEAL CANCER IN ACHALASIA: A PROPENSITY-MATCHED POPULATION-BASED STUDY FROM A LARGE MULTICENTER DATABASE","status":"ACTIVE_NOT_RECRUITING","sponsor":"IRCCS San Raffaele","startDate":"2025-06-03","conditions":"Achalasia Cardia, Esophageal Cancer (EsC)","enrollment":47000},{"nctId":"NCT06034938","phase":"PHASE2","title":"DOR/TDF/3TC Switch With M184V/I in People With Controlled HIV (Drive Off-Road)","status":"RECRUITING","sponsor":"University Hospital, Caen","startDate":"2024-02-08","conditions":"Hiv","enrollment":32},{"nctId":"NCT04665375","phase":"PHASE4","title":"Can INSTI-associated Weight Gain be Halted or Reversed With a Switch to Doravirine/Lamivudine/Tenofovir DF?","status":"TERMINATED","sponsor":"University Health Network, Toronto","startDate":"2021-04-26","conditions":"Hiv, Weight Gain","enrollment":4},{"nctId":"NCT04636437","phase":"PHASE4","title":"Doravirine for Obese Persons on Integrase Inhibitors and Tenofovir Alafenamide","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2021-07-27","conditions":"HIV Infections","enrollment":147},{"nctId":"NCT03410589","phase":"","title":"Development of a Computerized Adaptive Test (CAT) for Evaluation of Sleep, Fatigue and Quality of Life in Patients With Chronic Pain","status":"COMPLETED","sponsor":"University of Sao Paulo","startDate":"2019-01-01","conditions":"Chronic Pain","enrollment":308},{"nctId":"NCT06794047","phase":"NA","title":"The Effect of VitC on IVF Outcome of DOR Patients","status":"RECRUITING","sponsor":"Peking University Third Hospital","startDate":"2025-03-17","conditions":"Diminished Ovarian Reserve, IVF Outcomes","enrollment":1100},{"nctId":"NCT06774872","phase":"PHASE2","title":"Doravirine/Lamivudine (DOR/3TC) as a Maintenance ART in Comparison With Dolutegravir/Lamivudine (DTG/3TC) in PLWH Successfully","status":"RECRUITING","sponsor":"Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida","startDate":"2025-04-30","conditions":"HIV-1-infection","enrollment":408},{"nctId":"NCT06718244","phase":"PHASE2","title":"Inaticabtagene Autoleucel (Inati-cel; CNCT19) Treatment for MRD-Positive B-ALL Patients in CR1","status":"RECRUITING","sponsor":"Ruijin Hospital","startDate":"2024-12-10","conditions":"Acute Lymphoblastic Leukemia","enrollment":20},{"nctId":"NCT04669678","phase":"PHASE4","title":"Evaluation of Pharmacokinetic Drug-drug Interactions Between Hormonal Contraceptives and Doravirine-containing ART Among Women Living With HIV in South Africa","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2021-11-17","conditions":"HIV Infections, Contraception, Drug-drug Interaction","enrollment":110},{"nctId":"NCT05924438","phase":"PHASE3","title":"A Randomised, Phase 3 Non-inferiority Study of DOR/3TC/TDF Compared to DTG/TAF/FTC in Participants Infected With HIV-1 Starting First-line Antiretroviral Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Professor Francois Venter","startDate":"2023-11-08","conditions":"HIV-1-infection","enrollment":600},{"nctId":"NCT06725433","phase":"NA","title":"Nissen Versus Dor Hiatal Hernia Repair","status":"RECRUITING","sponsor":"Kuopio University Hospital","startDate":"2025-02-07","conditions":"Hiatal Hernia, Paraesophageal Hernia, Recurrence","enrollment":150},{"nctId":"NCT05790655","phase":"NA","title":"Ovarian PRP for Diminished Ovarian Reserve","status":"RECRUITING","sponsor":"Generation Next Fertility","startDate":"2023-10-07","conditions":"Diminished Ovarian Reserve","enrollment":230},{"nctId":"NCT06601452","phase":"EARLY_PHASE1","title":"Clinical Trial of Anovulatory Infertility","status":"ENROLLING_BY_INVITATION","sponsor":"Affiliated Hospital of Nanjing University of Chinese Medicine","startDate":"2024-09-30","conditions":"Polycystic Ovary Syndrome, Diminished Ovarian Reserve, Ovulation Disorder","enrollment":650},{"nctId":"NCT05477407","phase":"NA","title":"Adipose Tissue After Switch to Doravirine","status":"COMPLETED","sponsor":"Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida","startDate":"2022-10-06","conditions":"HIV Infections","enrollment":22},{"nctId":"NCT04815720","phase":"PHASE1, PHASE2","title":"Pepinemab in Combination With Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck","status":"COMPLETED","sponsor":"Vaccinex Inc.","startDate":"2021-08-09","conditions":"Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC)","enrollment":49},{"nctId":"NCT04233216","phase":"PHASE3","title":"Doravirine/Islatravir (DOR/ISL) in Heavily Treatment-Experienced (HTE) Participants for Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-019)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-03-18","conditions":"HIV-1 Infection","enrollment":35},{"nctId":"NCT05289986","phase":"PHASE4","title":"The Effect on Lipid Profile of Switching to Delstrigo in HIV Positive Patients","status":"TERMINATED","sponsor":"Chelsea and Westminster NHS Foundation Trust","startDate":"2023-11-21","conditions":"Hiv","enrollment":18},{"nctId":"NCT06096766","phase":"","title":"The Correlation Between Ovarian Function and Serum Biomarkers","status":"RECRUITING","sponsor":"Shi Yun","startDate":"2023-10-25","conditions":"Premature Ovarian Insufficiency, Diminished Ovarian Reserve, Biomarker","enrollment":35},{"nctId":"NCT06719570","phase":"PHASE1","title":"A Study of Doravirine and Islatravir as a Single Entity or Combination Therapy and the Effect of Food in Healthy Adult Participants (MK-8591A-055)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-01-23","conditions":"Healthy","enrollment":24},{"nctId":"NCT06037564","phase":"PHASE4","title":"B-free Multistage Trial","status":"ENROLLING_BY_INVITATION","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2023-11-13","conditions":"HIV, Drug Resistance, Drug Drug Interaction","enrollment":210},{"nctId":"NCT06660511","phase":"EARLY_PHASE1","title":"Exploratory Study on the Safety and Efficacy of Disitamab Vedotin in Combination with Anlotinib Hydrochloride for the Treatment of HER-2-expressing Recurrent Platinum-resistant Ovarian Cancer.","status":"RECRUITING","sponsor":"Second Xiangya Hospital of Central South University","startDate":"2024-10-15","conditions":"Ovarian Cancer Recurrent","enrollment":5},{"nctId":"NCT06621082","phase":"PHASE2","title":"The Clinical Study of the Treatment of Patients With Type I Neurofibromatosis With Smetinib Hydrosulfate Capsule","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2024-09-30","conditions":"Neurofibromatosis 1","enrollment":19},{"nctId":"NCT06617247","phase":"EARLY_PHASE1","title":"Effects of Cannabidiol on Burnout Syndrome and Empathy of Caregivers of Older Adults","status":"NOT_YET_RECRUITING","sponsor":"University of Sao Paulo","startDate":"2024-12-01","conditions":"Burnout Syndrome","enrollment":26},{"nctId":"NCT06602622","phase":"PHASE4","title":"Change in Body Weight and BMI in PWH with DOR/3TC/TDF Compared with INSTI","status":"RECRUITING","sponsor":"Instituto Mexicano del Seguro Social","startDate":"2024-08-14","conditions":"HIV, HIV Associate Weight Loss, HIV-1 Infection","enrollment":108},{"nctId":"NCT06369077","phase":"PHASE4","title":"How Much Does Reduced Dosing of Latanoprost and Dorzolamide-timolol Affect Pressure?","status":"TERMINATED","sponsor":"CT Glaucoma Associates","startDate":"2024-04-22","conditions":"Glaucoma, Open-Angle, Glaucoma; Drugs","enrollment":36},{"nctId":"NCT06426355","phase":"NA","title":"The Effeciency of NMN in Improving IVF/ICSI-ET Pregnancy Outcomes in Patients With DOR","status":"RECRUITING","sponsor":"Peking University Third Hospital","startDate":"2023-10-01","conditions":"Diminished Ovarian Reserve","enrollment":200},{"nctId":"NCT06395623","phase":"","title":"Study of Acupoints in Diminished Ovarian Reserve Based on Biological Characteristics","status":"RECRUITING","sponsor":"Xiaomei Shao","startDate":"2024-03-24","conditions":"Diminished Ovarian Reserve","enrollment":100},{"nctId":"NCT04295772","phase":"PHASE2","title":"Doravirine/Islatravir (DOR/ISL) in Pediatric Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are <18 Years of Age and Weigh ≥35 kg (MK-8591A-028)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-11-26","conditions":"HIV-1 Infection","enrollment":42},{"nctId":"NCT04470050","phase":"PHASE1, PHASE2","title":"Dexmedetomidine in the Treatment of Symptoms Of Acute Opioid Withdrawal","status":"COMPLETED","sponsor":"BioXcel Therapeutics Inc","startDate":"2020-06-09","conditions":"Opioid Withdrawal","enrollment":225},{"nctId":"NCT04447872","phase":"NA","title":"The LUTEAL Trial: Luteal Stimulation vs. Estrogen Priming Protocol","status":"UNKNOWN","sponsor":"Northwell Health","startDate":"2020-09-15","conditions":"Infertility, Diminished Ovarian Reserve, IVF","enrollment":142},{"nctId":"NCT05506605","phase":"PHASE4","title":"Switch Strategy From Etravirine (ETR) to Doravirine (DOR) in Virologically-Suppressed HIV-1 Infected Adults With ETR-Resistance","status":"UNKNOWN","sponsor":"Fundacion Clinic per a la Recerca Biomédica","startDate":"2022-12-12","conditions":"HIV-1-infection","enrollment":12},{"nctId":"NCT04433780","phase":"PHASE3","title":"DORA: A Doravirine-based First-line Antiretroviral Therapy for Women of Reproductive Potential Living With HIV","status":"COMPLETED","sponsor":"Professor Francois Venter","startDate":"2021-01-04","conditions":"HIV-1-infection","enrollment":133},{"nctId":"NCT01601678","phase":"NA","title":"Endoscopic Versus Laparoscopic Myotomy for Treatment of Idiopathic Achalasia","status":"COMPLETED","sponsor":"Universitätsklinikum Hamburg-Eppendorf","startDate":"2012-12","conditions":"Achalasia","enrollment":240},{"nctId":"NCT05457530","phase":"PHASE3","title":"Doravirine and Weight Gain in Antiretroviral Naive","status":"WITHDRAWN","sponsor":"Prism Health North Texas","startDate":"2022-08-01","conditions":"Body Weight Changes, Human Immunodeficiency Virus, ART","enrollment":""},{"nctId":"NCT03272347","phase":"PHASE2","title":"Islatravir (MK-8591) With Doravirine and Lamivudine in Participants Infected With Human Immunodeficiency Virus Type 1 (MK-8591-011)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2017-11-27","conditions":"HIV-1 Infection","enrollment":123},{"nctId":"NCT02980731","phase":"PHASE3","title":"A Study Evaluating the Impact of Venetoclax on the Quality of Life for Subjects With Relapsed (Your Cancer Has Come Back) or Refractory (no Response to Previous Cancer Treatments) Chronic Lymphocytic Leukemia (CLL) While Receiving Venetoclax Monotherapy (a Single Agent).","status":"COMPLETED","sponsor":"AbbVie","startDate":"2016-12-13","conditions":"Chronic Lymphocytic Leukemia (CLL)","enrollment":210},{"nctId":"NCT05729971","phase":"","title":"Nasogastric Tube After Laparoscopic Heller-Dor Myotomy","status":"COMPLETED","sponsor":"Federico II University","startDate":"2019-01-01","conditions":"Achalasia, Achalasia Cardia","enrollment":79},{"nctId":"NCT03332095","phase":"PHASE1, PHASE2","title":"Evaluating the Pharmacokinetics, Safety, and Tolerability of Doravirine (MK-1439) and Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (MK-1439A) in HIV-1-Infected Children and Adolescents","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2018-07-02","conditions":"HIV Infections","enrollment":55},{"nctId":"NCT05616364","phase":"PHASE2","title":"Compair Efficacy of iv Dexmedetomidine & Tramadol for Post Spinal Shivering in Obs Patients Undergoing Cesarean Section","status":"UNKNOWN","sponsor":"Sana Bahadur","startDate":"2023-03","conditions":"Post Spinal Shivering","enrollment":100},{"nctId":"NCT05577455","phase":"PHASE3","title":"Efficacy of Traditional Chinese Medicine on Ameliorating IVF-ET Outcomes of Diminished Ovarian Reserve Patients","status":"UNKNOWN","sponsor":"Peking University Third Hospital","startDate":"2022-11-10","conditions":"Diminished Ovarian Reserve, Infertility, Female","enrollment":266},{"nctId":"NCT04489420","phase":"PHASE1","title":"Natural Killer Cell (CYNK-001) IV Infusion or IT Administration in Adults With Recurrent GBM","status":"TERMINATED","sponsor":"Celularity Incorporated","startDate":"2020-10-01","conditions":"Astrocytoma, Grade IV, Giant Cell Glioblastoma, Glioblastoma Multiforme","enrollment":3},{"nctId":"NCT04429152","phase":"PHASE3","title":"ADORE: Efficacy of DORavirine in Adults Living With HIV Experiencing Virological Failure on First-line Efavirenz-based Antiretroviral Therapy With NNRTI Resistance","status":"UNKNOWN","sponsor":"Professor Francois Venter","startDate":"2021-02-09","conditions":"HIV-1-infection","enrollment":25},{"nctId":"NCT05385848","phase":"NA","title":"Autologous Platelet-rich Plasma (PRP) Infusion to Improve Outcomes in Women With Ovarian Insufficiency: a Pilot Study","status":"UNKNOWN","sponsor":"KK Women's and Children's Hospital","startDate":"2022-05","conditions":"Diminished Ovarian Reserve, Premature Ovarian Insufficiency, Fertility Issues","enrollment":30},{"nctId":"NCT05322083","phase":"","title":"HIV A6 Genome In ART Unsuccessful Patients On DOR","status":"UNKNOWN","sponsor":"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation","startDate":"2022-05","conditions":"Virus-HIV","enrollment":60},{"nctId":"NCT02629822","phase":"PHASE2","title":"Safety and Efficacy of Doravirine, Tenofovir, Lamivudine (MK-1439A) in Participants Infected With Treatment-Naïve Human Immunodeficiency Virus (HIV) -1 With Transmitted Resistance (MK-1439A-030)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2016-01-14","conditions":"HIV-1 Infection","enrollment":10},{"nctId":"NCT03631732","phase":"PHASE3","title":"Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2018-08-28","conditions":"HIV-1 Infection","enrollment":496},{"nctId":"NCT01614067","phase":"PHASE4","title":"Delayed Start to Ovarian Stimulation","status":"TERMINATED","sponsor":"University of California, San Francisco","startDate":"2012-05","conditions":"Diminished Ovarian Reserve, Infertility, In Vitro Fertilization","enrollment":30},{"nctId":"NCT01568164","phase":"NA","title":"Safety and Efficacy Study of the BioVentrix PliCath HF System","status":"COMPLETED","sponsor":"BioVentrix","startDate":"2012-03","conditions":"Heart Failure","enrollment":120},{"nctId":"NCT01568138","phase":"NA","title":"Prospective Study of the BioVentrix PliCath HF™ System for the Treatment of Ischemic Cardiomyopathy","status":"COMPLETED","sponsor":"BioVentrix","startDate":"2010-08","conditions":"Heart Failure","enrollment":26},{"nctId":"NCT03474120","phase":"","title":"Prospective Genetic Study in Patients With Ovarian Insufficiency","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Anhui Medical University","startDate":"2018-04-20","conditions":"Premature Ovarian Failure, Primary Ovarian Insufficiency, Ovarian Dysgenesis","enrollment":300},{"nctId":"NCT04706312","phase":"PHASE1","title":"Transplantation of hAMSCs for Woman With DOR","status":"UNKNOWN","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2021-04","conditions":"Diminished Ovarian Response","enrollment":12},{"nctId":"NCT04711772","phase":"","title":"Whole-genome Sequencing Study in Patients With Diminished Ovarian Reserve","status":"UNKNOWN","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2020-09-01","conditions":"Diminished Ovarian Reserve","enrollment":140},{"nctId":"NCT04490590","phase":"PHASE4","title":"A Clinical Trial of Chidamide Combined With Etoposide in Relapsed or Refractory NK/T-cell Lymphoma","status":"UNKNOWN","sponsor":"Mingzhi Zhang","startDate":"2016-10-01","conditions":"NK/T-Cell Lymphoma","enrollment":30},{"nctId":"NCT03886701","phase":"PHASE1","title":"Doravirine, Rifapentine and Isoniazid Interaction","status":"COMPLETED","sponsor":"Walter K. Kraft","startDate":"2019-04-22","conditions":"Latent Tuberculosis, Human Immunodeficiency Virus, Rifamycins Causing Adverse Effects in Therapeutic Use","enrollment":11},{"nctId":"NCT02179255","phase":"PHASE1, PHASE2","title":"Human Growth Hormone Pre-treatment for 6 Weeks Prior to Ovulation Induction for IVF","status":"UNKNOWN","sponsor":"Center for Human Reproduction","startDate":"2014-08-01","conditions":"Female Infertility Due to Diminished Ovarian Reserve","enrollment":30},{"nctId":"NCT04152902","phase":"","title":"Quality of Life After Surgery for End-stage Achalasia","status":"COMPLETED","sponsor":"University of Bologna","startDate":"1987-01","conditions":"Symptoms and Signs, Quality of Life","enrollment":60},{"nctId":"NCT02866253","phase":"PHASE4","title":"Dehydroepiandrosterone (DHEA)Supplementation Pre-IVF(In Vitro Fertilization) Cycles","status":"COMPLETED","sponsor":"ShangHai Ji Ai Genetics & IVF Institute","startDate":"2014-12","conditions":"Infertility","enrollment":78},{"nctId":"NCT03217370","phase":"NA","title":"Study on Patient Blood Management in Haematological Patients","status":"SUSPENDED","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2017-08-01","conditions":"Blood Transfusion, Haematology","enrollment":700},{"nctId":"NCT02225184","phase":"","title":"Impact of Delta Opioid Receptor Gene (OPRD1) Variations on Treatment Outcome in African Americans","status":"COMPLETED","sponsor":"National Institute on Drug Abuse (NIDA)","startDate":"2014-08-23","conditions":"Genetic Underpinning of Substance Abuse, Polymorphism-genetic, Drug Abuse/Dependence","enrollment":81},{"nctId":"NCT02110784","phase":"PHASE2","title":"Eurartesim® in Patients With Imported Uncomplicated Plasmodium Vivax Malaria","status":"TERMINATED","sponsor":"Alfasigma S.p.A.","startDate":"2014-06-18","conditions":"Malaria, Vivax","enrollment":27},{"nctId":"NCT03493334","phase":"NA","title":"Visual Feedback in Chronic Neck Pain","status":"COMPLETED","sponsor":"Aveiro University","startDate":"2018-04-15","conditions":"Neck Pain","enrollment":42},{"nctId":"NCT03562338","phase":"NA","title":"Predictive Model of Recovery in Patients With Chronic Nonspecific Neck Pain Undergoing Manual Therapy and Exercise","status":"UNKNOWN","sponsor":"Universidade Nova de Lisboa","startDate":"2018-06-11","conditions":"Chronic Nonspecific Neck Pain","enrollment":80},{"nctId":"NCT03560947","phase":"NA","title":"Individual Responder Analysis of the Effectiveness of Manual Therapy and Exercise Versus Usual Care in Patients With Chronic Nonspecific Neck Pain","status":"UNKNOWN","sponsor":"Universidade Nova de Lisboa","startDate":"2018-06-20","conditions":"Chronic Nonspecific Neck Pain","enrollment":46},{"nctId":"NCT02325518","phase":"PHASE4","title":"Comparison of Intraocular Pressure (IOP)-Lowering Efficacy and Safety of AZORGA® Ophthalmic Suspension and COSOPT® Ophthalmic Solution","status":"COMPLETED","sponsor":"Alcon, a Novartis Company","startDate":"2014-12","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":218},{"nctId":"NCT02366169","phase":"","title":"Medigus Ultrasonic Surgical Endostapler (MUSE) Registry","status":"UNKNOWN","sponsor":"Medigus Ltd","startDate":"2015-03","conditions":"Gastroesophageal Reflux Disease (GERD)","enrollment":200},{"nctId":"NCT00490750","phase":"NA","title":"Laparoscopic Dor Versus Toupet Fundoplication for the Treatment of Idiopathic Esophageal Achalasia","status":"COMPLETED","sponsor":"L. Michael Brunt","startDate":"2003-03","conditions":"Esophageal Achalasia","enrollment":60},{"nctId":"NCT00979953","phase":"PHASE2","title":"Efficacy and Safety Study Evaluating ADL5859 and ADL5747 in Participants With Pain Due to Osteoarthritis of the Knee","status":"COMPLETED","sponsor":"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","startDate":"2009-10","conditions":"Osteoarthritis of the Knee","enrollment":408},{"nctId":"NCT01058642","phase":"PHASE2","title":"Study to Assess the Efficacy, Safety, and Tolerability of ADL5747 in Participants With Postherpetic Neuralgia","status":"TERMINATED","sponsor":"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","startDate":"2010-01","conditions":"Postherpetic Neuralgia","enrollment":41},{"nctId":"NCT02150330","phase":"PHASE3","title":"Effects of Dehydroepiandrosterone Supplementation on Cumulus Cells Gene Expression Under Controlled Ovarian Hyper-stimulation in Patients With Diminished Ovarian Reserve","status":"COMPLETED","sponsor":"Taipei Veterans General Hospital, Taiwan","startDate":"2013-01","conditions":"Dehydroepiandrosterone, DHEAS, Gene Expression of Cumulus Cells.","enrollment":40},{"nctId":"NCT01933373","phase":"NA","title":"A Prospective Study Comparing Two Reconstructive Operation Techniques After Myotomy of Achalasia","status":"COMPLETED","sponsor":"Karolinska University Hospital","startDate":"2007-05","conditions":"Achalasia","enrollment":25},{"nctId":"NCT00970112","phase":"PHASE2, PHASE3","title":"Dexamethasone and Etoricoxib for Pain Prevention Following Periodontal Surgery","status":"COMPLETED","sponsor":"Universidade Estadual de Ponta Grossa","startDate":"2008-11","conditions":"Pain Control","enrollment":20},{"nctId":"NCT00794690","phase":"NA","title":"Safety Study of Black Cohosh Use by Postmenopausal Women on the Liver","status":"COMPLETED","sponsor":"Assiut University","startDate":"2008-01","conditions":"Menopause","enrollment":100}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6941,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Doravirine","MK-1439"],"phase":"marketed","status":"active","brandName":"DOR","genericName":"DOR","companyName":"Merck Sharp & Dohme LLC","companyId":"merck-sharp-dohme-llc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"DOR is a delta opioid receptor agonist that binds to and activates delta opioid receptors in the central and peripheral nervous system. Used for Chronic pain conditions.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}